Loading clinical trials...
Loading clinical trials...
A Double-Blind, Placebo-Controlled, Preliminary Study of the Efficacy, Safety, and Tolerability of Intravenous SUN N4057 in Patients With Motor Complications Associated With Parkinson's Disease
The purpose of this study is to obtain preliminary information on the effect of piclozotan on motor complications associated with Parkinson's Disease.
Age
40 - 85 years
Sex
ALL
Healthy Volunteers
No
The Parkinson's and Movement Disorder Institute
Fountain Valley, California, United States
University of South Florida, Parkinson's Disease and Movement Disorders Center
Tampa, Florida, United States
Emory University--Wesley Woods Health Center
Atlanta, Georgia, United States
UMDNJ-Robert Wood Johnson Medical School
New Brunswick, New Jersey, United States
Suny Downstate Medical Center
Brooklyn, New York, United States
Hospital Multimedica
Guatemala City, Guatemala
Hospital Clinic of Neurology and Psychiatry Oradea
Oradea, Romania
Start Date
July 13, 2007
Primary Completion Date
July 17, 2008
Completion Date
July 17, 2008
Last Updated
March 11, 2021
27
ACTUAL participants
piclozotan
DRUG
0.9% sodium chloride (normal saline)
DRUG
Lead Sponsor
Daiichi Sankyo
NCT02119611
NCT07310264
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07216976